Sequence information


DRAVP ID  DRAVPc009

Name   Thymalfasin

Sequence 

Molecular Formula  C129H215N33O55

Condition/Disease  HBV infection, HCV infection

Group  Approved

Type  Peptide

Description  A thymus hormone polypeptide found in thymosin fraction 5 (a crude thymus gland extract) but now produced by synthesis.Thymosin alpha 1 is now approved in 35 developing countries for the treatment of Hepatitis B and C. Thymalfasin is also used for the treatment of chemotherapy-induced immunosuppression, and to enhance the efficacy of influenza and hepatitis B vaccines in immunocompromised patients.

Active sequence/Structure 


External Links


DrugBank Accession Number  DB04900

Pubchem ID  16130571

CHEMBL ID  CHEMBL2103979

UNII  W0B22ISQ1C

CAS  62304-98-7

Reference  15482167  35434596 



ClinicalTrails Information


NCT Number Study Title Condition/Disease Status Phase Sponsor
NCT02281266 Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection Curable Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown Phase 4 Jia Fan
NCT03448744 Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients Chronic Hepatitis B virus infection Unknown Phase 4 Wen-hong Zhang
NCT04428008 Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients (Ta1) COVID-19 Recruiting Phase 2 Inova Health Care Services
NCT04487444 Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection (Ta1) COVID-19 Recruiting Phase 2 Rhode Island Hospital